Cagrilintide + Tirzepatide Dosage

Both cagrilintide and tirzepatide treat obesity. Each works through different receptors. The rationale for combining them rests on the triple-mechanism hypothesis: if semaglutide + cagrilintide (CagriSema) produced 20.4% weight loss in REDEFINE 1 over 68 weeks (Garvey et al., 2025), substituting tirzepatide for semaglutide should in theory match or exceed that result because tirzepatide is a dual GLP-1/GIP agonist that achieved 20.9% weight loss at the 15 mg dose in SURMOUNT-1 (Jastreboff et al., 2022).

Mechanism map: - Cagrilintide is a long-acting amylin analogue engineered with a fatty acid albumin-binding chain to extend half-life to support once-weekly dosing (Kruse et al., 2021). It binds amylin and calcitonin receptors, suppresses glucagon, slows gastric emptying, and reduces food intake via central hypothalamic signaling. - Tirzepatide is a dual GLP-1 and GIP receptor agonist. GLP-1 activation slows gastric emptying, increases satiety, and promotes insulin secretion. GIP activation increases adipocyte lipolysis and may reduce the nausea burden compared to GLP-1 alone. - The combined theory: hunger suppression from amylin, slowed gastric emptying from GLP-1, fat-cell metabolism signaling from GIP, and insulin sensitization across the board.

The missing evidence: no Phase 3 trial. The only published human trial data on this combination does not exist. The closest approximation is REDEFINE 1 (cagri + sema) and SURMOUNT-1 (tirzepatide alone), neither of which tested the cagri + tirz pair head-to-head. Anyone selling you a cagri + tirz protocol is extrapolating from these adjacent trials.

The current real-world picture: compounding pharmacies that offer both drugs sometimes market a co-administration protocol. This is a regulatory grey zone. Tirzepatide is FDA-approved and patented (Eli Lilly). Cagrilintide NDA was filed December 2025 and has not been approved. Compounded cagrilintide sits in the same "research peptide" category as retatrutide did before approval. For the legal and supply context, see FDA peptide crackdown and are peptides legal.

The most widely-used compounded protocol stacks the two weekly injections on the same day, escalates each on alternating months, and holds at maintenance doses indefinitely.

The core rule: never escalate both drugs in the same week. Each dose increase carries a 2 to 3-week window of elevated GI side effects. Stacking two increases in one week produces cumulative nausea that most patients cannot tolerate, and many discontinue the stack entirely.

Titration flexibility: Slower is always safer. If you reach a dose level that produces 5 to 7 days of nausea, hold that level for an extra 4 weeks before the next step. The CagriSema trial documented 79.6% GI adverse events at similar dose levels in the cagri + sema combination; tirzepatide monotherapy already carries 30 to 50% nausea. The combined rate is not published but logically sits in the 60 to 80% range during titration.

Injection day logistics: Both drugs are given subcutaneously, once weekly. Use two separate injection sites (for example, left abdomen for one, right thigh for the other). Never mix them in the same syringe. See best injection sites for tirzepatide and the tirzepatide dosage calculator for site rotation guidance.

CagriSema is Novo Nordisk's investigational drug: cagrilintide co-formulated with semaglutide, injected as a single weekly dose. Cagrilintide + tirzepatide is a compounded stack, not an FDA-approved product.

Key differences:

Why the GIP angle may (or may not) matter: Tirzepatide's GIP receptor activation is thought to contribute to its superior efficacy over semaglutide in SURMOUNT-1 vs STEP-1 (22.5% vs 14.9% mean weight loss). If that mechanism additively stacks with cagrilintide's amylin effect, the cagri + tirz combination could theoretically produce greater weight loss than CagriSema. But this is speculation until a head-to-head trial runs.

Why the stack might be worse, not better: Side effects from GLP-1, GIP, and amylin all converge on similar GI pathways. Nausea receptors stack nonlinearly. A 30% nausea rate from tirzepatide + 40% from cagrilintide does not equal 70%; the combined rate often exceeds 80% at peak titration, driving discontinuation. CagriSema's co-formulation at lower effective doses may have a better side effect profile than the stack.

For a complete rundown of cagrilintide monotherapy and CagriSema data, see cagrilintide weight loss dosage. For the tirzepatide-only protocol, see how to inject tirzepatide and tirzepatide dosage chart in units. For the survodutide alternative that also uses a triple-receptor mechanism, see survodutide vs tirzepatide.

The cumulative side effect burden is the single biggest reason to think twice about this stack.

Documented side effects (extrapolated from CagriSema + tirzepatide data): - Nausea: 40 to 60% during titration, declining to 10 to 20% at maintenance - Diarrhea: 20 to 30% at peak dose levels - Constipation: 15 to 25% (alternates with diarrhea for many patients) - Vomiting: 10 to 20% during dose increases - Injection site reactions: 5 to 10% per site - Pancreatitis (rare): same risk as either drug alone; not demonstrably additive - Thyroid C-cell tumors: boxed warning on tirzepatide applies

What to stop the stack for immediately: - Persistent severe abdominal pain (rule out pancreatitis) - Vomiting for more than 48 hours - Signs of severe dehydration - Neck mass or dysphagia (rule out thyroid pathology) - New onset mood changes or suicidal ideation (both drugs carry this warning)

Dose de-escalation rule: If you cannot tolerate the planned titration step, drop one level, hold 4 additional weeks, and retry. Never skip a dose of either drug at maintenance; a missed cagrilintide dose for more than 10 days essentially restarts the titration clock for that drug (tirzepatide has a 5-day half-life and is more forgiving).

Drug interactions: Both drugs slow gastric emptying, which can dramatically reduce absorption of oral medications taken within 2 hours of injection. This is particularly problematic for oral contraceptives, thyroid medications, and warfarin. See tirzepatide drug interactions for the complete interaction list that applies here.

For the full safety framework on GLP-1 stacking, see can tirzepatide cause anxiety and tirzepatide long-term side effects.

Reasonable candidates: - Patients who have plateaued on tirzepatide monotherapy at 15 mg for 6+ months and still have significant weight to lose - Patients under specialist care who understand this is an unapproved combination - Patients willing to tolerate slower titration than either drug alone would require

Poor candidates: - Someone starting their first GLP-1 agent (start with tirzepatide or semaglutide monotherapy first) - Anyone with BMI under 30 without metabolic comorbidities (risk/benefit does not justify a triple-agent stack) - History of pancreatitis, medullary thyroid carcinoma, or MEN-2 syndrome (both drugs contraindicated) - Pregnancy, breastfeeding, or planning conception within 2 months (both drugs contraindicated) - Anyone seeking this because online content called it the "next level". Marketing is not evidence

What the stack does not do: - Accelerate weight loss beyond what tirzepatide alone produces (unproven) - Reduce side effects compared to either drug alone (it increases them) - Replace the need for lifestyle change, protein intake, resistance training - Work without consistent weekly dosing

If plateau is your concern, first optimize the current protocol. Common fixes: increase protein to 1.6 to 2.0 g/kg lean body mass, add resistance training 3x weekly, ensure 7 to 9 hours of sleep, and audit hidden calorie sources. See why am I not losing weight on tirzepatide for the full plateau checklist before adding a second drug.